The Hackett Group, Inc. (NASDAQ: HCKT), a leading Gen AI consultancy and enterprise digital transformation firm, today ...

Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...

Technology may be sprinting forward, but lasting change still begins and ends with people. Over the past decade, I've watched RPA and low-code platforms sweep through global business services (GBS).

The last time I wrote about Annexon (ANNX) it was with respect to a Seeking Alpha article entitled "Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place". In this article ...

Seasoned GBS, Finance, and Transformation Executives Strengthen Aokah's AI + Expert Orchestration Platform NEW YORK, March 6, 2026 /PRNewswire/ -- ...